Wikipedia

Pramipexole

(Redirected from Mirapex)

Pramipexole, sold under the brand Mirapex among others, is a medication used to treat Parkinson's disease (PD) and restless legs syndrome (RLS).[8] In Parkinson's disease it may be used alone or together with levodopa.[8] It is taken by mouth.[8] Pramipexole is a dopamine agonist of the non-ergoline class.[8]

Pramipexole
Clinical data
Pronunciation/ˌpræmɪˈpɛksoʊl/
Trade namesMirapex, Mirapexin, Sifrol, others
AHFS/Drugs.comMonograph
MedlinePlusa697029
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability>90%
Protein binding15%
Elimination half-life8–12 hours
ExcretionUrine (90%), feces (2%)
Identifiers
  • (S)-N 6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.124.761 Edit this at Wikidata
Chemical and physical data
FormulaC10H17N3S
Molar mass211.33 g·mol−1
3D model (JSmol)
  • n1c2c(sc1N)C[C@@H](NCCC)CC2
  • InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1 checkY
  • Key:FASDKYOPVNHBLU-ZETCQYMHSA-N checkY
  (verify)

Pramipexole was approved for medical use in the United States in 1997.[8] It is available as a generic medication.[9] In 2021, it was the 209th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[10][11]

Medical uses

edit

Pramipexole is used in the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS).[8] Use in pregnancy and breastfeeding is of unclear safety.[1]

A 2008 meta-analysis found that Pramipexole was more effective than Ropinirole in the treatment of RLS.[12]

It is occasionally prescribed off-label for depression. Its effectiveness as an antidepressant may be a product of its strong partial agonistic activity on and preferential occupation of dopamine D3 receptors at low doses (see table below); as well, the drug has been shown to desensitize the inhibitory D2 autoreceptors but not the postsynaptic D2 receptors, leading to an increase in dopamine and serotonin levels in the prefrontal cortex.[13] Chronic administration of Pramipexole may also result in desensitization of D3 autoreceptors, leading to reduced dopamine transporter function.[14] Trials have shown mixed results for depression.[15]

Pramipexole has also been used as a treatment for REM sleep behaviour disorder, but it is not licensed for use in this disorder. Observational studies suggest it may reduce the frequency and intensity of REM sleep behavior disorder symptoms, but randomized controlled trials have not been performed, so the evidence for its role in this disorder is weak.[16]

Side effects

edit

Common side effects of Pramipexole may include:[17][4][5]

  • Headache
  • Peripheral edema[18]
  • Hyperalgesia (body aches and pains)
  • Nausea and vomiting
  • Sedation and somnolence
  • Decreased appetite and subsequent weight loss
  • Orthostatic hypotension (resulting in dizziness, lightheadedness, and possibly fainting, especially when standing up)
  • Insomnia
  • Hallucinations (seeing, hearing, smelling, tasting or feeling things that are not there), amnesia and confusion
  • Twitching, twisting, or other unusual body movements
  • Unusual tiredness or weakness
  • Pramipexole (and related D3-preferring dopamine agonist medications such as ropinirole) can induce "impulsive-compulsive spectrum disorders"[19] such as compulsive gambling, punding, hypersexuality, and overeating, even in people without any prior history of these behaviors.[20][21][22] There have also been reported detrimental side effects related to impulse-control disorders resulting from off-label use of Pramipexole or other dopamine agonists in treating clinical depression.[23] The incidence and severity of impulse-control disorders for those taking the drug for depression are not fully understood because the drug has not been approved for the treatment of depression and the first major studies of its efficacy in treating anhedonic depression were conducted in 2022. There have been anecdotal reports of abrupt and severe personality changes related to impulsivity and loss of self-control in a minority of patients regardless of the condition being treated, although the incidence of these side effects is not yet fully known.[23]
  • Augmentation:[a] Especially when used to treat restless legs syndrome, long-term Pramipexole treatment may exhibit drug augmentation, which is "an iatrogenic worsening of RLS symptoms following treatment with dopaminergic agents"[24] and may include an earlier onset of symptoms during the day or a generalized increase in symptoms.[25][26][27]

Pharmacology

edit

The activity profile of Pramipexole at various sites has been characterized as follows:

Activities of Pramipexole at various sites[28][29][30][31][32]
Site Affinity (Ki, nM) Efficacy (Emax, %) Action
D2S 3.3 130 Super agonist
D2L 3.9 70 Partial agonist
D3 0.5 70 Partial agonist
D4 3.9 42 Partial agonist
Notes: Pramipexole also possesses lower affinity (500–10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors.[28][33] It has negligible affinity (>10,000 nM) for the D1, D5, 5-HT2, α1-adrenergic, β-adrenergic, H1, and mACh receptors.[28][33] All sites were assayed using human materials.[28][29] Pramipexole is a super agonist at the presynaptic D2S receptor, S referring to a shorter amino acid sequence which desensitize overtime unlike postsynaptic D2L receptors.

While Pramipexole is used clinically (see below), its D3-preferring receptor binding profile has made it a popular tool compound for preclinical research. For example, Pramipexole has been used (in combination with D2- and or D3-preferring antagonists) to discover the role of D3 receptor function in rodent models and tasks for neuropsychiatric disorders.[34] Of note, it appears that Pramipexole , in addition to having effects on dopamine D3 receptors, may also affect mitochondrial function via a mechanism that remains less understood. A pharmacological approach to separate dopaminergic from non-dopaminergic (e.g. mitochondrial) effects of Pramipexole has been to study the effects of the R-stereoisomer of Pramipexole (which has much lower affinity to the dopamine receptors when compared to the S-isomer) side by side with the effects of the S-isomer.[35]

Parkinson's disease is a neurodegenerative disease affecting the substantia nigra, a component of the basal ganglia. The substantia nigra has a high quantity of dopaminergic neurons, which are nerve cells that release the neurotransmitter known as dopamine. When dopamine is released, it may activate dopamine receptors in the striatum, which is another component of the basal ganglia. When neurons of the substantia nigra deteriorate in Parkinson's disease, the striatum no longer properly receives dopamine signals. As a result, the basal ganglia can no longer regulate body movement effectively and motor function becomes impaired. By acting as an agonist for the D2, D3, and D4 dopamine receptors, Pramipexole may directly stimulate the underfunctioning dopamine receptors in the striatum, thereby restoring the dopamine signals needed for proper functioning of the basal ganglia.

Pramipexole can increase growth hormone indirectly through its inhibition of somatostatin.[36]

Society and culture

edit

Brand names

edit

Brand names include Mirapex, Mirapex ER, Mirapexin, Sifrol, Glepark, and Oprymea.[citation needed]

Research

edit

Pramipexole has been evaluated for the treatment of sexual dysfunction experienced by some users of selective serotonin reuptake inhibitor (SSRI) antidepressants.[37] Pramipexole has shown effects on pilot studies in a placebo-controlled proof of concept study in bipolar disorder.[38][39][40] It is also being investigated for the treatment of clinical depression and fibromyalgia.[41][42][43]

Derivatives

edit

Derivatives of Pramipexole include CJ-998, CJ-1037, CJ-1638, CJ-1639,[44] D-264, D-440,[45] and D-512.[45]

Explanatory notes

edit
  1. ^ The term "augmentation" has different meanings depending on the context. In the context of the pharmacological management of psychiatric disorders, for example, it means enhancing treatment effects by adding a second drug (or other treatment intervention). In the present context, augmentation has the meaning given above (in the body of the article).

References

edit
  1. ^ a b "Pramipexole Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 22 March 2019. Retrieved 3 March 2019.
  2. ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  3. ^ "Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
  4. ^ a b "Mirapex- pramipexole dihydrochloride tablet". DailyMed. 1 March 2020. Archived from the original on 18 October 2020. Retrieved 17 October 2020.
  5. ^ a b "Mirapex ER- pramipexole dihydrochloride tablet, extended release". DailyMed. 5 February 2020. Archived from the original on 21 October 2020. Retrieved 17 October 2020.
  6. ^ "Sifrol EPAR". European Medicines Agency. 17 November 2009. Archived from the original on 18 October 2020. Retrieved 17 October 2020.
  7. ^ "Mirapexin EPAR". European Medicines Agency. 17 November 2009. Archived from the original on 18 October 2020. Retrieved 17 October 2020.
  8. ^ a b c d e f "Pramipexole Dihydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 3 April 2019. Retrieved 22 March 2019.
  9. ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 417–418. ISBN 9780857113382.
  10. ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  11. ^ "Pramipexole - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  12. ^ Quilici S, Abrams KR, Nicolas A, Martin M, Petit C, Lleu PL, Finnern HW (October 2008). "Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome". Sleep Med. 9 (7): 715–26. doi:10.1016/j.sleep.2007.11.020. PMID 18226947.
  13. ^ Chernoloz O, El Mansari M, Blier P (February 2012). "Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain". Journal of Psychiatry & Neuroscience. 37 (2): 113–121. doi:10.1503/jpn.110038. PMC 3297071. PMID 22023785.
  14. ^ Castro-Hernández J, Afonso-Oramas D, Cruz-Muros I, Salas-Hernández J, Barroso-Chinea P, Moratalla R, et al. (February 2015). "Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake". Neurobiology of Disease. 74: 325–335. doi:10.1016/j.nbd.2014.12.007. PMID 25511804. S2CID 25373392.
  15. ^ Fawcett J, Rush AJ, Vukelich J, Diaz SH, Dunklee L, Romo P, et al. (February 2016). "Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression". The American Journal of Psychiatry. 173 (2): 107–111. doi:10.1176/appi.ajp.2015.15060788. PMID 26844792.
  16. ^ Tan SM, Wan YM (30 September 2016). "Pramipexole in the treatment of REM sleep behaviour disorder: A critical review". Psychiatry Res. 243: 365–372. doi:10.1016/j.psychres.2016.06.055. PMID 27449005. S2CID 4854211.
  17. ^ "MedlinePlus Drug Information: Pramipexole (Systemic)". United States National Library of Medicine. Archived from the original on 26 September 2006. Retrieved 27 September 2006.
  18. ^ Tan EK, Ondo W (May 2000). "Clinical characteristics of pramipexole-induced peripheral edema". Archives of Neurology. 57 (5): 729–732. doi:10.1001/archneur.57.5.729. PMID 10815140.
  19. ^ Napier TC, Kirby A, Persons AL (August 2020). "The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson's disease". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 102: 109942. doi:10.1016/j.pnpbp.2020.109942. PMID 32272129. S2CID 215237629. ... features of ICSDs [impulsive-compulsive spectrum disorders] during D2/D3R treatment are consistent with the pharmacological profile of the drugs, the known role of D2/D3R in these behaviors, and the neuroanatomical substrates of D2/D3R-expressing brain systems of ICSDs as shown by modern human imaging studies. While we pose that D2/D3R agonist treatment is sufficient to mediate ICSDs, there likely are many factors that overlay this profile, e.g., genetic vulnerabilities, brain disease state, and maladaptations to the chronic therapy.
  20. ^ Bostwick JM, Hecksel KA, Stevens SR, Bower JH, Ahlskog JE (April 2009). "Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease". Mayo Clinic Proceedings. 84 (4): 310–316. doi:10.4065/84.4.310. PMC 2665974. PMID 19339647.
  21. ^ Moore TJ, Glenmullen J, Mattison DR (December 2014). "Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs". JAMA Internal Medicine. 174 (12): 1930–1933. doi:10.1001/jamainternmed.2014.5262. PMID 25329919.
  22. ^ Wolters EC, van der Werf YD, van den Heuvel OA (September 2008). "Parkinson's disease-related disorders in the impulsive-compulsive spectrum". Journal of Neurology. 255 (Suppl 5): 48–56. doi:10.1007/s00415-008-5010-5. PMID 18787882. S2CID 24531331.
  23. ^ a b Elliott C. "The Degradation Drug". The American Scholar. Archived from the original on 15 September 2022. Retrieved 15 September 2022.
  24. ^ Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen AV, et al. (July 2018). "Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§". Movement Disorders. 33 (7): 1077–1091. doi:10.1002/mds.27260. PMID 29756335. S2CID 21669996. Archived from the original on 3 July 2022. Retrieved 13 November 2022. … the specific goals of the current review were to … separately identify the RLS-specific side effect, which is augmentation.
  25. ^ "Pramipexole Monograph for Professionals". Drugs.com. Archived from the original on 25 November 2021. Retrieved 11 December 2020. Augmentation of symptoms of restless legs syndrome (e.g., earlier onset of symptoms in the evening or afternoon, increase in symptoms, spread of symptoms to involve other extremities) reported; incidence increased with increasing duration of pramipexole treatment.
  26. ^ Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo W, Trenkwalder C, et al. (December 2016). "Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology". Neurology. 87 (24): 2585–2593. doi:10.1212/WNL.0000000000003388. PMC 5206998. PMID 27856776.
  27. ^ Salminen AV, Winkelmann J (November 2018). "Restless Legs Syndrome and Other Movement Disorders of Sleep-Treatment Update". Current Treatment Options in Neurology. 20 (12): 55. doi:10.1007/s11940-018-0540-3. PMID 30411165. S2CID 53242049. Archived from the original on 12 July 2022. Retrieved 12 July 2022. … augmentation of the RLS symptoms is a major limitation of oral dopaminergic therapy.
  28. ^ a b c d Kvernmo T, Härtter S, Burger E (August 2006). "A review of the receptor-binding and pharmacokinetic properties of dopamine agonists". Clinical Therapeutics. 28 (8): 1065–1078. doi:10.1016/j.clinthera.2006.08.004. PMID 16982285.
  29. ^ a b Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 805–814. doi:10.1124/jpet.102.039875. PMID 12388667. S2CID 35238120.
  30. ^ Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM (June 1995). "Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors". European Journal of Pharmacology. 290 (1): 29–36. doi:10.1016/0922-4106(95)90013-6. PMID 7664822.
  31. ^ "PDSP Ki Database Pramipexole Query". PDSP Ki Database. UNC. Archived from the original on 11 October 2023. Retrieved 11 July 2022.
  32. ^ "Pramipexole dihydrochloride characteristics". Bio-techne. Archived from the original on 12 July 2022. Retrieved 11 July 2022.
  33. ^ a b Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 791–804. doi:10.1124/jpet.102.039867. PMID 12388666. S2CID 6200455.
  34. ^ Weber M, Chang WL, Breier M, Ko D, Swerdlow NR (December 2008). "Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation". Behavioural Pharmacology. 19 (8): 786–795. doi:10.1097/FBP.0b013e32831c3b2b. PMC 3255557. PMID 19020413.
  35. ^ Chang WL, Weber M, Breier MR, Saint Marie RL, Hines SR, Swerdlow NR (February 2012). "Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats". Brain Research. 1437: 69–76. doi:10.1016/j.brainres.2011.12.007. PMC 3268831. PMID 22227455.
  36. ^ Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM (November 2007). "Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers". British Journal of Clinical Pharmacology. 64 (5): 591–602. doi:10.1111/j.1365-2125.2007.02938.x. PMC 2203276. PMID 17578485.
  37. ^ DeBattista C, Solvason HB, Breen JA, Schatzberg AF (April 2000). "Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression". Journal of Clinical Psychopharmacology. 20 (2): 274–275. doi:10.1097/00004714-200004000-00029. PMID 10770475.
  38. ^ Zarate CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, et al. (July 2004). "Pramipexole for bipolar II depression: a placebo-controlled proof of concept study". Biological Psychiatry. 56 (1): 54–60. doi:10.1016/j.biopsych.2004.03.013. PMID 15219473. S2CID 19613411. Archived from the original on 8 September 2021. Retrieved 3 August 2019.
  39. ^ Goldberg JF, Burdick KE, Endick CJ (March 2004). "Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression". The American Journal of Psychiatry. 161 (3): 564–566. doi:10.1176/appi.ajp.161.3.564. PMID 14992985.
  40. ^ Goodwin GM, Martinez-Aran A, Glahn DC, Vieta E (November 2008). "Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report". European Neuropsychopharmacology. 18 (11): 787–793. doi:10.1016/j.euroneuro.2008.07.005. PMID 18725178. S2CID 18520604.
  41. ^ Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, et al. (October 2002). "Pramipexole in treatment-resistant depression: a 16-week naturalistic study". Bipolar Disorders. 4 (5): 307–314. doi:10.1034/j.1399-5618.2002.01171.x. PMID 12479663.
  42. ^ Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A, Cassano GB (2004). "Pramipexole in treatment-resistant depression: an extended follow-up". Depression and Anxiety. 20 (3): 131–138. doi:10.1002/da.20038. PMID 15549689. S2CID 23007562.
  43. ^ Holman AJ, Myers RR (August 2005). "A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications". Arthritis and Rheumatism. 52 (8): 2495–2505. doi:10.1002/art.21191. PMID 16052595.
  44. ^ Chen J, Collins GT, Levant B, Woods J, Deschamps JR, Wang S (August 2011). "CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist". ACS Medicinal Chemistry Letters. 2 (8): 620–625. doi:10.1021/ml200100t. PMC 3224040. PMID 22125662.
  45. ^ a b Santra S, Xu L, Shah M, Johnson M, Dutta A (October 2013). "D-512 and D-440 as novel multifunctional dopamine agonists: characterization of neuroprotection properties and evaluation of in vivo efficacy in a Parkinson's disease animal model". ACS Chemical Neuroscience. 4 (10): 1382–1392. doi:10.1021/cn400106n. PMC 3798991. PMID 23906010.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Pramipexole&oldid=1247929557"